Claims for Patent: 9,346,817

Summary for Patent: 9,346,817

Title:	Dioxino- and oxazin-[2,3-D]pyrimidine PI3K inhibitor compounds and methods of use
Abstract:	Dioxino- and oxazin-[2,3-d]pyrimidine PI3K inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. ##STR00001##
Inventor(s):	Heald; Robert Andrew (Harlow, GB), McLean; Neville James (Harlow, GB)
Assignee:	Genentech, Inc. (South San Francisco, CA)
Application Number:	14/013,256
Patent Claims:	1. A compound selected from Formula Ia: ##STR00078## and stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein: R.sup.1 and R.sup.2 are independently selected from H, .dbd.O, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.8 alkenyl, C.sub.2-C.sub.8 alkynyl, and C.sub.3-C.sub.12 carbocyclyl, where alkyl and carbocyclyl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, --CH.sub.3, --CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH.sub.3, --CH.sub.2CN, --CN, --CF.sub.3, --CH.sub.2OH, --CO.sub.2H, --CONH.sub.2, --CONH(CH.sub.3), --CON(CH.sub.3).sub.2, --NO.sub.2, --NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2, --NHCOCH.sub.3, --OH, .dbd.O, --OCH.sub.3, --OCH.sub.2CH.sub.3, --OCH(CH.sub.3).sub.2, --SH, --NHC(.dbd.O)NHCH.sub.3, --NHC(.dbd.O)NHCH.sub.2CH.sub.3, --NHC(.dbd.O)NHCH(CH.sub.3).sub.2, --NHS(O).sub.2CH.sub.3, --N(CH.sub.3)C(.dbd.O)OC(CH.sub.3).sub.3, --S(O).sub.2CH.sub.3, benzyl, benzyloxy, cyclopropyl, morpholinyl, morpholinomethyl, and 4-methylpiperazin-1-yl; or two R.sup.1 groups and the carbon to which they are attached form a spiro, 3- to 6-membered carbocyclic or heterocyclic ring; or two R.sup.2 groups and the carbon to which they are attached form a spiro, 3- to 6-membered carbocyclic or heterocyclic ring; and R.sup.3 is selected from C.sub.6-C.sub.20 aryl, C.sub.2-C.sub.20 heterocyclyl and C.sub.1-C.sub.20 heteroaryl, each of which are optionally substituted with one or more groups independently selected from F, Cl, Br, I, --CH.sub.3, --CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --CH.sub.2CH(CH.sub.3).sub.2, --CH.sub.2CH.sub.3, --CH.sub.2CN, --CN, --CF.sub.3, --CH.sub.2OH, --CO.sub.2H, --CONH.sub.2, --CONH(CH.sub.3), --CON(CH.sub.3).sub.2, --NO.sub.2, --NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2, --NHCOCH.sub.3, --OH, --OCH.sub.3, --OCH.sub.2CH.sub.3, --OCH(CH.sub.3).sub.2, --SH, --NHC(.dbd.O)NHCH.sub.3, --NHC(.dbd.O)NHCH.sub.2CH.sub.3, --NHC(.dbd.O)NHCH(CH.sub.3).sub.2, --NHS(O).sub.2CH.sub.3, --N(CH.sub.3)C(.dbd.O)OC(CH.sub.3).sub.3, --S(O).sub.2CH.sub.3, benzyl, benzyloxy, morpholinyl, morpholinomethyl, and 4-methylpiperazin-1-yl. 2. The compound of claim 1 wherein R.sup.1 is independently selected from H, --CH.sub.3, --CH.sub.2CH.sub.3, --C(CH.sub.3).sub.3, --CH.sub.2OH, --CH.sub.2CH.sub.2OH, --C(CH.sub.3).sub.2OH, --CH.sub.2OCH.sub.3, --CN, --CH.sub.2F, --CHF.sub.2, and --CF.sub.3. 3. The compound of claim 1 wherein R.sup.1 is independently selected from H, --CH.sub.3, and cyclopropyl. 4. The compound of claim 1 wherein R.sup.2 is independently selected from H, --CH.sub.3, --C(CH.sub.3).sub.3, --CH.sub.2OH, --CF.sub.3, --CH.sub.2F, and cyclopropyl. 5. The compound of claim 4 wherein R.sup.2 are each --CH.sub.3. 6. The compound of claim 1 wherein two R.sup.2 groups and the carbon to which they are attached form .dbd.O or cyclopropyl. 7. The compound of claim 1 wherein R.sup.3 is phenyl substituted with one or more groups selected from F, Cl, Br, I, --CH.sub.3, --CH.sub.2CH.sub.3, --CH(CH.sub.3).sub.2, --CN, --CF.sub.3, --CH.sub.2OH, --CO.sub.2H, --CONH.sub.2, --CONH(CH.sub.3), --CON(CH.sub.3).sub.2, --NO.sub.2, --NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2, NHCOCH.sub.3, --OH, --OCH.sub.3, --OCH.sub.2CH.sub.3, --OCH(CH.sub.3).sub.2, --SH, --NHC(.dbd.O)NHCH.sub.3, --NHC(.dbd.O)NHCH.sub.2CH.sub.3, --NHS(O).sub.2CH.sub.3, --N(CH.sub.3)C(.dbd.O)OC(CH.sub.3).sub.3, and --S(O).sub.2CH.sub.3. 8. The compound of claim 1 wherein R.sup.3 is an optionally substituted bicyclic heteroaryl group selected from 1H-indazole, 1H-indole, indolin-2-one, 1-(indolin-1-yl)ethanone, 1H-benzo[d][1,2,3]triazole, 1H-pyrazolo[3,4-b]pyridine, 1H-pyrazolo[3,4-d]pyrimidine, 1H-benzo[d]imidazole, 1H-benzo[d]imidazol-2(3H)-one, 1H-pyrazolo[3,4-c]pyridine, 1H-pyrrolo[2,3-c]pyridine, 3H-imidazo[4,5-c]pyridine, 7H-pyrrolo[2,3-d]pyrimidine, 7H-purine, 1H-pyrazolo[4,3-d]pyrimidine, 5H-pyrrolo[3,2-d]pyrimidine, 2-amino-1H-purin-6(9H)-one, quinoline, quinazoline, quinoxaline, isoquinoline, isoquinolin-1(2H)-one, 3,4-dihydroisoquinolin-1(2H)-one, 3,4-dihydroquinolin-2(1H)-one, quinazolin-2(1H)-one, quinoxalin-2(1H)-one, 1,8-naphthyridine, pyrido[3,4-d]pyrimidine, and pyrido[3,2-b]pyrazine. 9. The compound of claim 1 wherein optionally substituted R.sup.3 is selected from: ##STR00079## ##STR00080## ##STR00081## where the wavy line indicates the site of attachment. 10. The compound of claim 9 wherein R.sup.3 is 1H-indazol-4-yl. 11. The compound of claim 1 wherein R.sup.3 is an optionally substituted monocyclic heteroaryl group selected from 2-furanyl, 3-furanyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-pyrazolyl, 4-pyrazolyl, 2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 2-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 5-tetrazolyl, 1-tetrazolyl, 2-tetrazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-triazolyl, and 1-triazolyl. 12. The compound of claim 11 wherein R.sup.3 is 2-aminopyrimidin-5-yl. 13. The compound of claim 1 wherein optionally substituted R.sup.3 is selected from: ##STR00082## where the wavy line indicates the site of attachment. 14. A compound of claim 1 selected from: 5-(4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-yl)pyrimidin-2- -amine; 5-[(6R)-6-methyl-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrim- idin-2-yl]pyrimidin-2-amine; 5-(7-methyl-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-yl)py- rimidin-2-amine; 5-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-2-yl)pyrimid- in-2-amine; 5-[4-morpholino-7-(trifluoromethyl)-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimi- din-2-yl]pyrimidin-2-amine; 5-(4-morpholinospiro[6H-[1,4]dioxino[2,3-d]pyrimidine-7,1'-cyclopropane]-- 2-yl)pyrimidin-2-amine; 5-(6-cyclopropyl-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-- yl)pyrimidin-2-amine; 5-(7-tert-butyl-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-y- l)pyrimidin-2-amine; 3-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-2-yl)phenol; 2-(2-methoxypyrimidin-5-yl)-7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3- -d]pyrimidine; 5-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-2-yl)pyridin- -2-amine; N-[4-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-- 2-yl)phenyl]acetamide; 5-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-2-yl)-N-meth- yl-pyridin-2-amine; N-[3-(7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimidin-2-yl)phen- yl]methanesulfonamide; 2-(1H-indol-5-yl)-7,7-dimethyl-4-morpholino-6H-[1,4]dioxino[2,3-d]pyrimid- ine; 5-[7-(fluoromethyl)-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrim- idin-2-yl]pyrimidin-2-amine; [2-(2-aminopyrimidin-5-yl)-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]py- rimidin-7-yl]methanol; and 5-(7-cyclopropyl-4-morpholino-6,7-dihydro-[1,4]dioxino[2,3-d]pyrimidin-2-- yl)pyrimidin-2-amine. 15. A pharmaceutical composition comprised of a compound of claim 1 and a pharmaceutically acceptable carrier, glidant, diluent, or excipient. 16. The pharmaceutical composition according to claim 15, further comprising an additional therapeutic agent selected from a chemotherapeutic agent, an anti-inflammatory agent, an immunomodulatory agent, a neurotropic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disorders. 17. A method of treating cancer in a patient comprised of administering to said patient a therapeutically effective amount of a compound of claim 1 wherein the cancer is breast, ovary, cervix, prostate, testis, genitourinary tract, esophagus, larynx, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, non-small cell lung carcinoma (NSCLC), small cell carcinoma, lung adenocarcinoma, bone, colon, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, renal, pancreatic, myeloid disorders, lymphoma, hairy cells, buccal cavity, naso-pharyngeal, pharynx, lip, tongue, mouth, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, Hodgkin's or leukemia. 18. The method of claim 17 wherein the cancer is a brain cancer. 19. The method of claim 17 further comprising administering to the patient an additional therapeutic agent selected from a chemotherapeutic agent, an anti-angiogenesis therapeutic agent, an anti-inflammatory agent, an immunomodulatory agent, a neurotropic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an anti-viral agent, an agent for treating blood disorders, an agent for treating diabetes, and an agent for treating immunodeficiency disorders. 20. The method of claim 19 wherein the additional therapeutic agent is bevacizumab. 21. A process for making a pharmaceutical composition which comprises combining a compound of claim 1 with a pharmaceutically acceptable carrier. 22. A kit for treating brain cancer, comprising: a) a first pharmaceutical composition comprising a compound of claim 1; and b) instructions for use.

Details for Patent 9,346,817

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2039-02-26